Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial
Myocardial ischemia induces intracellular accumulation of non-glycosylated apolipoprotein J that results in a reduction of circulating glycosylated ApoJ (ApoJ-Glyc). The latter has been suggested to be a marker of transient myocardial ischemia. This proof-of-concept clinical study aimed to assess wh...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2023-11, Vol.391, p.131291-131291, Article 131291 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 131291 |
|---|---|
| container_issue | |
| container_start_page | 131291 |
| container_title | International journal of cardiology |
| container_volume | 391 |
| creator | Kaski, Juan Carlos Lluch, Nuria Lopez-Sendon, Jose-Luis Gorog, Diana A. Antorrena-Miranda, Isabel Avanzas, Pablo Herrero Puente, Pablo Sionis, Alessandro González-Juanatey, José R. Íñiguez, Andrés Cordero, Alberto Ako, Emmanuel Fernández-Avilés, Francisco Atienza, Felipe Recio-Mayoral, Alejandro Wu, Alan H.B. Crea, Filippo Storey, Robert Badimon, Lina Cubedo, Judit |
| description | Myocardial ischemia induces intracellular accumulation of non-glycosylated apolipoprotein J that results in a reduction of circulating glycosylated ApoJ (ApoJ-Glyc). The latter has been suggested to be a marker of transient myocardial ischemia.
This proof-of-concept clinical study aimed to assess whether changes in circulating ApoJ-Glyc could detect myocardial ischemia in patients attending the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS).
In suspected ACS patients, EDICA (Early Detection of Myocardial Ischemia in Suspected Acute Coronary Syndromes by ApoJ-Glyc a Novel Pathologically based Ischemia Biomarker), a multicentre, international, cohort study assessed changes in 2 glycosylated variants of ApoJ-Glyc, (ApoJ-GlycA2 and ApoJ-GlycA6), in serum samples obtained at ED admission (0 h), and 1 h and 3 h thereafter, blinded to the clinical diagnosis (i.e. STEMI, NSTEMI, unstable angina, non-ischemic).
404 patients were recruited; 291 were given a clinical diagnosis of “non-ischemic” chest pain and 113 were considered to have had an ischemic event. ApoJ-GlycA6 was lower on admission in ischemic compared with “non-ischemic” patients (66 [46–90] vs. 73 [56–95] μg/ml; P = 0.04). 74% of unstable angina patients (all with undetectable hs-Tn), had ischemic changes in ApoJ-Glyc at 0 h and 89% at 1 h. Initially low ApoJ-Glyc levels in 62 patients requiring coronary revascularization increased significantly after successful percutaneous intervention.
Circulating ApoJ-Glyc concentrations decrease early in ED patients with myocardial ischemia compared with “non-ischemic” patients, even in the absence of troponin elevations. ApoJ-Glyc may be a useful marker of myocardial ischemia in the ED setting.
•ApoJ-Glyc detects reversible myocardial ischemia and the restoration of perfusion.•ApoJ-Glyc is a dynamic marker of transient/reversible myocardial ischemia.•ApoJ-Glyc might complement the diagnostic role of hs-Tn in the Emergency Department. |
| doi_str_mv | 10.1016/j.ijcard.2023.131291 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2857840372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527323011701</els_id><sourcerecordid>2857840372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-7b111b226e6b65da30f88c9fa59a475d0c7cb54a06e6c5782c2f9fe42e5267ac3</originalsourceid><addsrcrecordid>eNp9kD1PwzAURS0EEqXwDxg8sqTYzocTBqSqlAKqxFJmy3l5aR3SJNhJUf89LmFmesM990rvEHLL2YwzntxXM1OBtsVMMBHOeMhFxs_IhKcyCriMo3My8ZgMYiHDS3LlXMUYi7IsnZDPxU43W3TUNBSMhaHWvWm2dN61b8GqPgKt8YD1b975CJve0W_T76gbXIfQY0E1DD1SaG3baHuk7tgUtt3jA93skC6fXhdz2luj62tyUera4c3fnZKP5-Vm8RKs31ceWgcg0rQPZM45z4VIMMmTuNAhK9MUslLHmY5kXDCQkMeRZh6AWKYCRJmVGAmMRSI1hFNyN-52tv0a0PVqbxxgXesG28EpkfpWxEIpPBqNKNjWOYul6qzZ-y8UZ-rkVlVqdKtObtXo1tcex5o3gweDVjnwagALY70TVbTm_4Efkw2Etg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857840372</pqid></control><display><type>article</type><title>Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial</title><source>Access via ScienceDirect (Elsevier)</source><creator>Kaski, Juan Carlos ; Lluch, Nuria ; Lopez-Sendon, Jose-Luis ; Gorog, Diana A. ; Antorrena-Miranda, Isabel ; Avanzas, Pablo ; Herrero Puente, Pablo ; Sionis, Alessandro ; González-Juanatey, José R. ; Íñiguez, Andrés ; Cordero, Alberto ; Ako, Emmanuel ; Fernández-Avilés, Francisco ; Atienza, Felipe ; Recio-Mayoral, Alejandro ; Wu, Alan H.B. ; Crea, Filippo ; Storey, Robert ; Badimon, Lina ; Cubedo, Judit</creator><creatorcontrib>Kaski, Juan Carlos ; Lluch, Nuria ; Lopez-Sendon, Jose-Luis ; Gorog, Diana A. ; Antorrena-Miranda, Isabel ; Avanzas, Pablo ; Herrero Puente, Pablo ; Sionis, Alessandro ; González-Juanatey, José R. ; Íñiguez, Andrés ; Cordero, Alberto ; Ako, Emmanuel ; Fernández-Avilés, Francisco ; Atienza, Felipe ; Recio-Mayoral, Alejandro ; Wu, Alan H.B. ; Crea, Filippo ; Storey, Robert ; Badimon, Lina ; Cubedo, Judit</creatorcontrib><description>Myocardial ischemia induces intracellular accumulation of non-glycosylated apolipoprotein J that results in a reduction of circulating glycosylated ApoJ (ApoJ-Glyc). The latter has been suggested to be a marker of transient myocardial ischemia.
This proof-of-concept clinical study aimed to assess whether changes in circulating ApoJ-Glyc could detect myocardial ischemia in patients attending the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS).
In suspected ACS patients, EDICA (Early Detection of Myocardial Ischemia in Suspected Acute Coronary Syndromes by ApoJ-Glyc a Novel Pathologically based Ischemia Biomarker), a multicentre, international, cohort study assessed changes in 2 glycosylated variants of ApoJ-Glyc, (ApoJ-GlycA2 and ApoJ-GlycA6), in serum samples obtained at ED admission (0 h), and 1 h and 3 h thereafter, blinded to the clinical diagnosis (i.e. STEMI, NSTEMI, unstable angina, non-ischemic).
404 patients were recruited; 291 were given a clinical diagnosis of “non-ischemic” chest pain and 113 were considered to have had an ischemic event. ApoJ-GlycA6 was lower on admission in ischemic compared with “non-ischemic” patients (66 [46–90] vs. 73 [56–95] μg/ml; P = 0.04). 74% of unstable angina patients (all with undetectable hs-Tn), had ischemic changes in ApoJ-Glyc at 0 h and 89% at 1 h. Initially low ApoJ-Glyc levels in 62 patients requiring coronary revascularization increased significantly after successful percutaneous intervention.
Circulating ApoJ-Glyc concentrations decrease early in ED patients with myocardial ischemia compared with “non-ischemic” patients, even in the absence of troponin elevations. ApoJ-Glyc may be a useful marker of myocardial ischemia in the ED setting.
•ApoJ-Glyc detects reversible myocardial ischemia and the restoration of perfusion.•ApoJ-Glyc is a dynamic marker of transient/reversible myocardial ischemia.•ApoJ-Glyc might complement the diagnostic role of hs-Tn in the Emergency Department.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2023.131291</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Acute coronary syndrome ; Acute myocardial ischemia ; Angina ; Glycosylated ApoJ ; Ischemia</subject><ispartof>International journal of cardiology, 2023-11, Vol.391, p.131291-131291, Article 131291</ispartof><rights>2023 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c288t-7b111b226e6b65da30f88c9fa59a475d0c7cb54a06e6c5782c2f9fe42e5267ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2023.131291$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Kaski, Juan Carlos</creatorcontrib><creatorcontrib>Lluch, Nuria</creatorcontrib><creatorcontrib>Lopez-Sendon, Jose-Luis</creatorcontrib><creatorcontrib>Gorog, Diana A.</creatorcontrib><creatorcontrib>Antorrena-Miranda, Isabel</creatorcontrib><creatorcontrib>Avanzas, Pablo</creatorcontrib><creatorcontrib>Herrero Puente, Pablo</creatorcontrib><creatorcontrib>Sionis, Alessandro</creatorcontrib><creatorcontrib>González-Juanatey, José R.</creatorcontrib><creatorcontrib>Íñiguez, Andrés</creatorcontrib><creatorcontrib>Cordero, Alberto</creatorcontrib><creatorcontrib>Ako, Emmanuel</creatorcontrib><creatorcontrib>Fernández-Avilés, Francisco</creatorcontrib><creatorcontrib>Atienza, Felipe</creatorcontrib><creatorcontrib>Recio-Mayoral, Alejandro</creatorcontrib><creatorcontrib>Wu, Alan H.B.</creatorcontrib><creatorcontrib>Crea, Filippo</creatorcontrib><creatorcontrib>Storey, Robert</creatorcontrib><creatorcontrib>Badimon, Lina</creatorcontrib><creatorcontrib>Cubedo, Judit</creatorcontrib><title>Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial</title><title>International journal of cardiology</title><description>Myocardial ischemia induces intracellular accumulation of non-glycosylated apolipoprotein J that results in a reduction of circulating glycosylated ApoJ (ApoJ-Glyc). The latter has been suggested to be a marker of transient myocardial ischemia.
This proof-of-concept clinical study aimed to assess whether changes in circulating ApoJ-Glyc could detect myocardial ischemia in patients attending the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS).
In suspected ACS patients, EDICA (Early Detection of Myocardial Ischemia in Suspected Acute Coronary Syndromes by ApoJ-Glyc a Novel Pathologically based Ischemia Biomarker), a multicentre, international, cohort study assessed changes in 2 glycosylated variants of ApoJ-Glyc, (ApoJ-GlycA2 and ApoJ-GlycA6), in serum samples obtained at ED admission (0 h), and 1 h and 3 h thereafter, blinded to the clinical diagnosis (i.e. STEMI, NSTEMI, unstable angina, non-ischemic).
404 patients were recruited; 291 were given a clinical diagnosis of “non-ischemic” chest pain and 113 were considered to have had an ischemic event. ApoJ-GlycA6 was lower on admission in ischemic compared with “non-ischemic” patients (66 [46–90] vs. 73 [56–95] μg/ml; P = 0.04). 74% of unstable angina patients (all with undetectable hs-Tn), had ischemic changes in ApoJ-Glyc at 0 h and 89% at 1 h. Initially low ApoJ-Glyc levels in 62 patients requiring coronary revascularization increased significantly after successful percutaneous intervention.
Circulating ApoJ-Glyc concentrations decrease early in ED patients with myocardial ischemia compared with “non-ischemic” patients, even in the absence of troponin elevations. ApoJ-Glyc may be a useful marker of myocardial ischemia in the ED setting.
•ApoJ-Glyc detects reversible myocardial ischemia and the restoration of perfusion.•ApoJ-Glyc is a dynamic marker of transient/reversible myocardial ischemia.•ApoJ-Glyc might complement the diagnostic role of hs-Tn in the Emergency Department.</description><subject>Acute coronary syndrome</subject><subject>Acute myocardial ischemia</subject><subject>Angina</subject><subject>Glycosylated ApoJ</subject><subject>Ischemia</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAURS0EEqXwDxg8sqTYzocTBqSqlAKqxFJmy3l5aR3SJNhJUf89LmFmesM990rvEHLL2YwzntxXM1OBtsVMMBHOeMhFxs_IhKcyCriMo3My8ZgMYiHDS3LlXMUYi7IsnZDPxU43W3TUNBSMhaHWvWm2dN61b8GqPgKt8YD1b975CJve0W_T76gbXIfQY0E1DD1SaG3baHuk7tgUtt3jA93skC6fXhdz2luj62tyUera4c3fnZKP5-Vm8RKs31ceWgcg0rQPZM45z4VIMMmTuNAhK9MUslLHmY5kXDCQkMeRZh6AWKYCRJmVGAmMRSI1hFNyN-52tv0a0PVqbxxgXesG28EpkfpWxEIpPBqNKNjWOYul6qzZ-y8UZ-rkVlVqdKtObtXo1tcex5o3gweDVjnwagALY70TVbTm_4Efkw2Etg</recordid><startdate>20231115</startdate><enddate>20231115</enddate><creator>Kaski, Juan Carlos</creator><creator>Lluch, Nuria</creator><creator>Lopez-Sendon, Jose-Luis</creator><creator>Gorog, Diana A.</creator><creator>Antorrena-Miranda, Isabel</creator><creator>Avanzas, Pablo</creator><creator>Herrero Puente, Pablo</creator><creator>Sionis, Alessandro</creator><creator>González-Juanatey, José R.</creator><creator>Íñiguez, Andrés</creator><creator>Cordero, Alberto</creator><creator>Ako, Emmanuel</creator><creator>Fernández-Avilés, Francisco</creator><creator>Atienza, Felipe</creator><creator>Recio-Mayoral, Alejandro</creator><creator>Wu, Alan H.B.</creator><creator>Crea, Filippo</creator><creator>Storey, Robert</creator><creator>Badimon, Lina</creator><creator>Cubedo, Judit</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231115</creationdate><title>Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial</title><author>Kaski, Juan Carlos ; Lluch, Nuria ; Lopez-Sendon, Jose-Luis ; Gorog, Diana A. ; Antorrena-Miranda, Isabel ; Avanzas, Pablo ; Herrero Puente, Pablo ; Sionis, Alessandro ; González-Juanatey, José R. ; Íñiguez, Andrés ; Cordero, Alberto ; Ako, Emmanuel ; Fernández-Avilés, Francisco ; Atienza, Felipe ; Recio-Mayoral, Alejandro ; Wu, Alan H.B. ; Crea, Filippo ; Storey, Robert ; Badimon, Lina ; Cubedo, Judit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-7b111b226e6b65da30f88c9fa59a475d0c7cb54a06e6c5782c2f9fe42e5267ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute coronary syndrome</topic><topic>Acute myocardial ischemia</topic><topic>Angina</topic><topic>Glycosylated ApoJ</topic><topic>Ischemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaski, Juan Carlos</creatorcontrib><creatorcontrib>Lluch, Nuria</creatorcontrib><creatorcontrib>Lopez-Sendon, Jose-Luis</creatorcontrib><creatorcontrib>Gorog, Diana A.</creatorcontrib><creatorcontrib>Antorrena-Miranda, Isabel</creatorcontrib><creatorcontrib>Avanzas, Pablo</creatorcontrib><creatorcontrib>Herrero Puente, Pablo</creatorcontrib><creatorcontrib>Sionis, Alessandro</creatorcontrib><creatorcontrib>González-Juanatey, José R.</creatorcontrib><creatorcontrib>Íñiguez, Andrés</creatorcontrib><creatorcontrib>Cordero, Alberto</creatorcontrib><creatorcontrib>Ako, Emmanuel</creatorcontrib><creatorcontrib>Fernández-Avilés, Francisco</creatorcontrib><creatorcontrib>Atienza, Felipe</creatorcontrib><creatorcontrib>Recio-Mayoral, Alejandro</creatorcontrib><creatorcontrib>Wu, Alan H.B.</creatorcontrib><creatorcontrib>Crea, Filippo</creatorcontrib><creatorcontrib>Storey, Robert</creatorcontrib><creatorcontrib>Badimon, Lina</creatorcontrib><creatorcontrib>Cubedo, Judit</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaski, Juan Carlos</au><au>Lluch, Nuria</au><au>Lopez-Sendon, Jose-Luis</au><au>Gorog, Diana A.</au><au>Antorrena-Miranda, Isabel</au><au>Avanzas, Pablo</au><au>Herrero Puente, Pablo</au><au>Sionis, Alessandro</au><au>González-Juanatey, José R.</au><au>Íñiguez, Andrés</au><au>Cordero, Alberto</au><au>Ako, Emmanuel</au><au>Fernández-Avilés, Francisco</au><au>Atienza, Felipe</au><au>Recio-Mayoral, Alejandro</au><au>Wu, Alan H.B.</au><au>Crea, Filippo</au><au>Storey, Robert</au><au>Badimon, Lina</au><au>Cubedo, Judit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial</atitle><jtitle>International journal of cardiology</jtitle><date>2023-11-15</date><risdate>2023</risdate><volume>391</volume><spage>131291</spage><epage>131291</epage><pages>131291-131291</pages><artnum>131291</artnum><issn>0167-5273</issn><eissn>1874-1754</eissn><abstract>Myocardial ischemia induces intracellular accumulation of non-glycosylated apolipoprotein J that results in a reduction of circulating glycosylated ApoJ (ApoJ-Glyc). The latter has been suggested to be a marker of transient myocardial ischemia.
This proof-of-concept clinical study aimed to assess whether changes in circulating ApoJ-Glyc could detect myocardial ischemia in patients attending the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS).
In suspected ACS patients, EDICA (Early Detection of Myocardial Ischemia in Suspected Acute Coronary Syndromes by ApoJ-Glyc a Novel Pathologically based Ischemia Biomarker), a multicentre, international, cohort study assessed changes in 2 glycosylated variants of ApoJ-Glyc, (ApoJ-GlycA2 and ApoJ-GlycA6), in serum samples obtained at ED admission (0 h), and 1 h and 3 h thereafter, blinded to the clinical diagnosis (i.e. STEMI, NSTEMI, unstable angina, non-ischemic).
404 patients were recruited; 291 were given a clinical diagnosis of “non-ischemic” chest pain and 113 were considered to have had an ischemic event. ApoJ-GlycA6 was lower on admission in ischemic compared with “non-ischemic” patients (66 [46–90] vs. 73 [56–95] μg/ml; P = 0.04). 74% of unstable angina patients (all with undetectable hs-Tn), had ischemic changes in ApoJ-Glyc at 0 h and 89% at 1 h. Initially low ApoJ-Glyc levels in 62 patients requiring coronary revascularization increased significantly after successful percutaneous intervention.
Circulating ApoJ-Glyc concentrations decrease early in ED patients with myocardial ischemia compared with “non-ischemic” patients, even in the absence of troponin elevations. ApoJ-Glyc may be a useful marker of myocardial ischemia in the ED setting.
•ApoJ-Glyc detects reversible myocardial ischemia and the restoration of perfusion.•ApoJ-Glyc is a dynamic marker of transient/reversible myocardial ischemia.•ApoJ-Glyc might complement the diagnostic role of hs-Tn in the Emergency Department.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ijcard.2023.131291</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2023-11, Vol.391, p.131291-131291, Article 131291 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2857840372 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | Acute coronary syndrome Acute myocardial ischemia Angina Glycosylated ApoJ Ischemia |
| title | Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T04%3A55%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20circulating%20ApoJ-Glyc%20levels%20in%20patients%20with%20suspected%20acute%20coronary%20syndrome:%20The%20EDICA%20trial&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Kaski,%20Juan%20Carlos&rft.date=2023-11-15&rft.volume=391&rft.spage=131291&rft.epage=131291&rft.pages=131291-131291&rft.artnum=131291&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2023.131291&rft_dat=%3Cproquest_cross%3E2857840372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857840372&rft_id=info:pmid/&rft_els_id=S0167527323011701&rfr_iscdi=true |